What are the practical, translational implications of LEADER and how might we explain, mechanistically or physiologically, the reduction in MACE events observed in the liraglutide group?

What are the practical, translational implications of LEADER and how might we explain, mechanistically or physiologically, the reduction in MACE events observed in the liraglutide group?

What are the practical, translational implications of LEADER and how might we explain, mechanistically or physiologically, the reduction in MACE events observed in the liraglutide group?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Josep Vidal, MD, PhD

Josep Vidal, MD, PhD

Obesity Unit, Endocrinology and Diabetes Unit
University Hospital Clinic
Barcelona, Spain